General Information of Drug (ID: DM87SOX)

Drug Name
Carbocyclic Peptidomimetic Drug Info
Synonyms
Carbocyclic Peptidomimetic; CHEMBL434943; OM99-2 cyclopentano analog 3; BDBM16049; N-{[(1R,2R)-2-{(1S,2S)-2-[(L-alpha-glutamyl-L-valyl-L-asparaginyl)amino]-1-hydroxy-4-methylpentyl}cyclopentyl]carbonyl}-L-alanyl-L-alpha-glutamyl-L-phenylalanine; (4S)-4-[(2S)-2-{[(1R,2R)-2-[(1S,2S)-2-[(2S)-2-[(2S)-2-[(4S)-4-amino-4-formamidobutanoic acid]-3-methylbutanamido]butanediamido]-1-hydroxy-4-methylpentyl]cyclopentyl]formamido}propanamido]-4-{[(1S)-1-carboxy-2-phenylethyl]carbamoyl}butanoic acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
11205295
TTD Drug ID
DM87SOX

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Cathepsin D (CTSD)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID10498202C1 DMXE0F2 Multiple sclerosis 8A40 Clinical trial [2]
CI-992 DMBHYIJ Hypertension BA00-BA04 Terminated [3]
Alpha-D-Mannose DMF5DLW Discovery agent N.A. Investigative [4]
Grassystatin a DM1PWX2 Discovery agent N.A. Investigative [5]
PMID8410973C3 DM6J5KY Discovery agent N.A. Investigative [6]
KNI-10006 DMMISH6 Discovery agent N.A. Investigative [7]
GRL-7234 DMR93MK Discovery agent N.A. Investigative [8]
S-Methylcysteine DMAMRKS Discovery agent N.A. Investigative [4]
N-Aminoethylmorpholine DMWXBYC Discovery agent N.A. Investigative [4]
1h-Benoximidazole-2-Carboxylic Acid DMNZAVE Discovery agent N.A. Investigative [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Beta-secretase (BACE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
(S)-FLURBIPROFEN DMF2O4T Myalgia FB56.2 Preregistration [9]
E-2609 DMTNUJ8 Alzheimer disease 8A20 Phase 3 [10]
verubecestat DM4CGH5 Alzheimer disease 8A20 Phase 3 [11]
Lanabecestat DMFJLB6 Alzheimer disease 8A20 Phase 3 [12]
AZD3293 DMJQHXD Alzheimer disease 8A20 Phase 2/3 [13]
JNJ-54861911 DMGPJ5U Alzheimer disease 8A20 Phase 2/3 [12]
R-flurbiprofen DMFIVSR N. A. N. A. Phase 2 [9]
LY2886721 DMV14LM Alzheimer disease 8A20 Phase 2 [14]
LY3202626 DM7IFNB Alzheimer disease 8A20 Phase 2 [12]
AZD-3839 DM72FOD Alzheimer disease 8A20 Phase 1 [15]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Beta-secretase (BACE) TT8JRS7 NOUNIPROTAC Inhibitor [1]
Cathepsin D (CTSD) TTPT2QI CATD_HUMAN Inhibitor [1]

References

1 Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. J Med Chem. 2005 Aug 11;48(16):5175-90.
2 Synthesis and structure activity relationships of novel small molecule cathepsin D inhibitors. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2531-6.
3 Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors. J Med Chem. 1992 Jul 10;35(14):2562-72.
4 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
5 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
6 Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. J Med Chem. 1993 Sep 3;36(18):2614-20.
7 alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases. Bioorg Med Chem. 2009 Aug 15;17(16):5933-49.
8 Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J Med Chem. 2007 May 17;50(10):2399-407.
9 The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
10 Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014 March; 13(3): 319-329.
11 BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89.
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13 AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF A-beta peptides following single- and multiple-dose administration. Neurobiology of Aging. May 20, 2008.
14 Lessons from a BACE1 inhibitor trial: off-site but not off base.Alzheimers Dement.2014 Oct;10(5 Suppl):S411-9.
15 Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem. 2012 Nov 30;287(49):41245-57.